MedTrace Logo

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

NCT00020969 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-10-05

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have myelodysplastic syndromes.

Conditions

Interventions

DRUG

arsenic trioxide

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • CTI BioPharma

    lead INDUSTRY

Principal Investigators

  • Scott C. Stromatt, MD · CTI BioPharma

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Primary Completion
2005-01-31
Completion
2005-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00020969 on ClinicalTrials.gov